MedTrace Logo

Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers

NCT01237028 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2016-09-07

No results posted yet for this study

Summary

This study will help to show the efficacy of vitamin D and address the optimal strategy to minimize renal injury in IgAN patients.

Conditions

Interventions

DRUG

Calcitriol

Calcitriol(1,25-dihydroxycholecalciferol, vitamin D3 analog)0.25 μg per day

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Tae-Hyun Yoo, MD, Ph.D · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01237028 on ClinicalTrials.gov